Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Summary

This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with metastatic kidney cancer.

Timeline

Start

2016-11-15

Primary completion

2020-08-05

Completion

2021-02-24

Drugs

Indications